Literature DB >> 2015632

Characterization of the human IL-5 receptors on eosinophils.

M Migita1, N Yamaguchi, S Mita, S Higuchi, Y Hitoshi, Y Yoshida, M Tomonaga, I Matsuda, A Tominaga, K Takatsu.   

Abstract

Interleukin 5 (IL-5) receptors on the cell surface of human eosinophils and other hematopoietic cells were characterized using radiolabeled recombinant IL-5. The binding of 35S-labeled murine IL-5 to eosinophils from normal human peripheral blood was rapid and saturable within a 30-min incubation at both 4 and 37 degrees C. The binding of 35S-labeled murine IL-5 to eosinophils was inhibited by an excess of unlabeled murine and human IL-5 or by an anti-murine IL-5 monoclonal antibody (NC17) but not by other human cytokines. Scatchard plot analysis revealed that human eosinophils have a single class of high affinity receptor (Kd 170-330 pM; number of binding sites: 260-380/cell). IL-5 receptors on eosinophils from four patients with eosinophilia displayed similar characteristics. Affinity cross-linking experiments resulted in the identification of human IL-5 receptor on eosinophils with a molecular mass of 55-60 kDa. Among the various cells besides eosinophils and cell lines that we could test, a subline of HL-60 (YY-1 cells) was found to display a significant number of IL-5 receptor. These results suggest that IL-5 may act on limited types of cells in the human system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015632     DOI: 10.1016/0008-8749(91)90120-z

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  16 in total

Review 1.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

Review 2.  Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.

Authors:  Aasia Ghazi; Anita Trikha; William J Calhoun
Journal:  Expert Opin Biol Ther       Date:  2011-12-05       Impact factor: 4.388

Review 3.  Eosinophils: multifaceted biological properties and roles in health and disease.

Authors:  Hirohito Kita
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

Review 4.  Novel Therapies for Eosinophilic Disorders.

Authors:  Bruce S Bochner
Journal:  Immunol Allergy Clin North Am       Date:  2015-08       Impact factor: 3.479

Review 5.  Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.

Authors:  El-Bdaoui Haddad; Sonya L Cyr; Kazuhiko Arima; Robert A McDonald; Noah A Levit; Frank O Nestle
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-21

6.  Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge.

Authors:  Mats W Johansson; Elizabeth A B Kelly; William W Busse; Nizar N Jarjour; Deane F Mosher
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

7.  Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.

Authors:  Meirav Zaks-Zilberman; Adrian E Harrington; Tetsuya Ishino; Irwin M Chaiken
Journal:  J Biol Chem       Date:  2008-03-07       Impact factor: 5.157

8.  Expression and in vitro properties of guinea pig IL-5: comparison to human and murine orthologs.

Authors:  C W Scott; C Budzilowicz; S J Hubbs; M Stein; C Sobotka-Briner; D E Wilkins
Journal:  Mediators Inflamm       Date:  2000       Impact factor: 4.711

Review 9.  Molecular immunology and immunotherapy for chronic sinusitis.

Authors:  Lily H P Nguyen; Samer Fakhri; Saul Frenkiel; Qutayba A Hamid
Journal:  Curr Allergy Asthma Rep       Date:  2003-11       Impact factor: 4.919

10.  Molecular cloning and expression of the human interleukin 5 receptor.

Authors:  Y Murata; S Takaki; M Migita; Y Kikuchi; A Tominaga; K Takatsu
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.